Active	Status	Sponsor type	Region	Phase	Filter
12 Active 4 Inactive 16 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

12 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Goldberg, Roger A
STAMP, NCT03832179: Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification	Recruiting	4	32	US	Bevacizumab, Avastin, Ranibizumab, Lucentis, Aflibercept, Eylea, Ozurdex, Dexamethasone implant	Bay Area Retina Associates, Allergan	Diabetic Macular Edema, Cataract	07/22	10/22
NCT05753670: Effect of Preoperative Tamsulosin on Postoperative Urinary Retention	Completed	3	183	US	Tamsulosin, Placebo	NorthShore University HealthSystem	Postoperative Retention of Urine	05/24	06/24
ARCHER II, NCT06510816: A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of ANX007 in Participants With Geographic Atrophy (GA)	Recruiting	3	630	Europe, Canada, US, RoW	ANX007, Sham Administration	Annexon, Inc.	Geographic Atrophy	10/26	10/27
NCT06397131: A Study to Determine the Safety and Efficacy of NT-501 With MHFM	Active, not recruiting	3	12	US	NT-501 CNTF Implant	Neurotech Pharmaceuticals	Macular Telangiectasia Type 2	04/26	07/26
ASPIRE, NCT06011798: Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME	Active, not recruiting	2	52	US	Aflibercept, foselutoclax, UBX1325	Unity Biotechnology, Inc.	Diabetic Macular Edema, Retinal Disease, Macular Edema, Diabetes Mellitus, Diabetic Retinopathy, Retinal Degeneration, Retinal Diseases, Eye Diseases, Edema	03/25	06/25
MAGNIFY, NCT05893537: Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).	Terminated	2	100	US	Active Comparator CT1812, Placebo Comparator	Cognition Therapeutics	Age-Related Macular Degeneration	03/25	03/25
NCT05345769: Safety and Efficacy of AM712 in Patients with NAMD	Completed	1	21	US	AM712(ASKG712)	AffaMed Therapeutics Limited	Neovascular Age-related Macular Degeneration	11/24	11/24
NCT05904691: Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration	Recruiting	1	19	US	OCU-10-C-110 for Injection	Ocugenix Corporation	Neovascular Age-related Macular Degeneration (nAMD)	11/26	11/26
NCT04881721: Mesh-free Suture Urethropexy for Treating Stress Urinary Incontinence, Efficacy and Durability Trial	Active, not recruiting	N/A	15	US	Urethropexy	NorthShore University HealthSystem	Stress Urinary Incontinence	12/23	12/23
PROD, NCT05747027: Prospective Randomized Controlled Trial of Obstructed Defecation Surgery	Recruiting	N/A	120	US	Laparoscopic abdominal ventral rectopexy, Transvaginal sacrospinous rectopexy	Endeavor Health, Weill Medical College of Cornell University, University of Pittsburgh	Obstructed Defecation, Pelvic Organ Prolapse	02/28	02/28
Paggiarino, Dario A
NCT05322070: Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis	Active, not recruiting	4	125	US	Fluocinolone Acetonide Intravitreal Implant 0.18 mg, YUTIQ 0.18 mg	Alimera Sciences, CBCC Global Research	Uveitis, Posterior	11/25	11/25
Boss, Joseph
NCT05322070: Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis	Active, not recruiting	4	125	US	Fluocinolone Acetonide Intravitreal Implant 0.18 mg, YUTIQ 0.18 mg	Alimera Sciences, CBCC Global Research	Uveitis, Posterior	11/25	11/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Goldberg, Roger A
STAMP, NCT03832179: Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification	Recruiting	4	32	US	Bevacizumab, Avastin, Ranibizumab, Lucentis, Aflibercept, Eylea, Ozurdex, Dexamethasone implant	Bay Area Retina Associates, Allergan	Diabetic Macular Edema, Cataract	07/22	10/22
NCT05753670: Effect of Preoperative Tamsulosin on Postoperative Urinary Retention	Completed	3	183	US	Tamsulosin, Placebo	NorthShore University HealthSystem	Postoperative Retention of Urine	05/24	06/24
ARCHER II, NCT06510816: A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of ANX007 in Participants With Geographic Atrophy (GA)	Recruiting	3	630	Europe, Canada, US, RoW	ANX007, Sham Administration	Annexon, Inc.	Geographic Atrophy	10/26	10/27
NCT06397131: A Study to Determine the Safety and Efficacy of NT-501 With MHFM	Active, not recruiting	3	12	US	NT-501 CNTF Implant	Neurotech Pharmaceuticals	Macular Telangiectasia Type 2	04/26	07/26
ASPIRE, NCT06011798: Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME	Active, not recruiting	2	52	US	Aflibercept, foselutoclax, UBX1325	Unity Biotechnology, Inc.	Diabetic Macular Edema, Retinal Disease, Macular Edema, Diabetes Mellitus, Diabetic Retinopathy, Retinal Degeneration, Retinal Diseases, Eye Diseases, Edema	03/25	06/25
MAGNIFY, NCT05893537: Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).	Terminated	2	100	US	Active Comparator CT1812, Placebo Comparator	Cognition Therapeutics	Age-Related Macular Degeneration	03/25	03/25
NCT05345769: Safety and Efficacy of AM712 in Patients with NAMD	Completed	1	21	US	AM712(ASKG712)	AffaMed Therapeutics Limited	Neovascular Age-related Macular Degeneration	11/24	11/24
NCT05904691: Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration	Recruiting	1	19	US	OCU-10-C-110 for Injection	Ocugenix Corporation	Neovascular Age-related Macular Degeneration (nAMD)	11/26	11/26
NCT04881721: Mesh-free Suture Urethropexy for Treating Stress Urinary Incontinence, Efficacy and Durability Trial	Active, not recruiting	N/A	15	US	Urethropexy	NorthShore University HealthSystem	Stress Urinary Incontinence	12/23	12/23
PROD, NCT05747027: Prospective Randomized Controlled Trial of Obstructed Defecation Surgery	Recruiting	N/A	120	US	Laparoscopic abdominal ventral rectopexy, Transvaginal sacrospinous rectopexy	Endeavor Health, Weill Medical College of Cornell University, University of Pittsburgh	Obstructed Defecation, Pelvic Organ Prolapse	02/28	02/28
Paggiarino, Dario A
NCT05322070: Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis	Active, not recruiting	4	125	US	Fluocinolone Acetonide Intravitreal Implant 0.18 mg, YUTIQ 0.18 mg	Alimera Sciences, CBCC Global Research	Uveitis, Posterior	11/25	11/25
Boss, Joseph
NCT05322070: Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis	Active, not recruiting	4	125	US	Fluocinolone Acetonide Intravitreal Implant 0.18 mg, YUTIQ 0.18 mg	Alimera Sciences, CBCC Global Research	Uveitis, Posterior	11/25	11/25